No Data
Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth
Express News | Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Press Release: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)
Russell U.S. Indexes Shift to Semi-annual Reconstitution From Annual, IREN in Russell 1000
152498972 : I chickened out early lost out